Novartis' MS drug Gilenia cuts relapse rates, moving it forward in race with Merck KGaA's cladribine

13 April 2010

Swiss drug major Novartis has presented positive new data for its multiple sclerosis drug Gilenia (fingolimod; FTY720) at the American Academy for Neurology (AAN) meeting taking place in Toronto, Canada, showing that the product reduced annual relapse rates by 62% for treatment-naive patients compared to placebo and by 44% for subjects who had received previous treatment, such as Avonex (interferon beta 1a).

Gilenia, which is under regulatory review in the USA and Europe, and has received priority status from the US Food and Drug Administration, is in a race to be the first oral MS treatment to reach the market, competing with German drugmaker Merck KGaA's cladribine which was filed in the USA last September, but the FDA rejected the filing two months later as incomplete, thus delayed the drug's approval (The Pharma Letter February 22).

Peak sales of $2-$2.5 billion forecast

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK